CADL — Candel Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1841387 ·
Last close
$10.01
Market Cap
$733.44M
52W High
$11.36
52W Low
$6.11
ADV30
1,769,586
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -16,262,000 | -8,861,000 | 201,920,000 | 194,834,000 | 63,891,000 |
| Dec 2025 | 0 | — | -15,663,000 | -29,496,000 | 125,195,000 | 119,731,000 | 73,273,000 |
| Sep 2025 | 0 | — | -13,207,000 | -11,269,000 | 93,598,000 | 86,963,000 | 13,474,000 |
| Jun 2025 | 0 | — | -11,177,000 | -4,796,000 | 105,968,000 | 100,687,000 | 15,758,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-47,732,000
Investing CF
$-1,232,000
Financing CF
$151,783,000
CapEx
$-1,259,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.98
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-239,248,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-51,045,000
Pretax Income TTM
$-54,422,000
Interest Exp TTM
$3,377,000
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -48,177,000 | -38,182,000 | 125,195,000 | 73,273,000 | — | -38,311,000 |
| Dec 2024 | 0 | -33,371,000 | -55,177,000 | 106,866,000 | 40,539,000 | — | -27,023,000 |
| Dec 2023 | 0 | -38,391,000 | -37,939,000 | 41,201,000 | 28,456,000 | — | -34,244,000 |
| Dec 2022 | 125,000 | -34,674,000 | -18,794,000 | 77,691,000 | 29,977,000 | — | -31,419,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.60
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AURA | Aura Biosciences, Inc. | $725.09M | $7.01 | — |
| SLDB | Solid Biosciences Inc. | $793.50M | $8.06 | — |
| DBVT | DBV Technologies S.A. | $799.04M | $13.50 | — |
| ALLO | Allogene Therapeutics, Inc. | $648.89M | $1.88 | — |
| AGMB | Agomab Therapeutics NV | $633.82M | $12.87 | — |
News headlines (Yahoo Finance, 1h cache)
Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston
2026-07-29 12:05 · Yahoo
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-07-08 20:05 · Yahoo
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-01 20:05 · Yahoo
CADL Stock Heads For Biggest Monthly Gains Since December 2024 – Retail Says ‘Our SLS Days Are Coming’
2026-06-30 16:27 · Yahoo
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response
2026-06-30 12:05 · Yahoo
Candel Therapeutics Designates Mark Sims as CCO
2026-06-25 19:53 · Yahoo
Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer
2026-06-25 12:05 · Yahoo
CADL Stock Heads For Best Week In A Month – Here’s Why Retail Is Bullish
2026-06-05 10:23 · Yahoo
Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Loca
2026-06-02 12:05 · Yahoo
Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data
2026-05-20 15:13 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.